Skip to content

Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments


Hørsholm, Denmark 23 May 2022

Gubra, a leader in preclinical services within metabolic and fibrotic diseases, and with a strong pipeline of novel discovery projects, today released its 2021 annual report showing a 53% increase in revenue to DKK 261 million and a more than 260% increase in EBITDA to DKK 115 million. The results are driven by organic growth across several key segments in the research contract service business combined with significant milestone payments from partnerships with blue chip pharma companies.

Henrik Blou, CEO of Gubra, said: “2021 became the best financial year on record, both in terms of revenue and earnings, as we continued to help our customers to progress their preclinical development for metabolic and fibrotic diseases. We also signed two new partnerships with Boehringer Ingelheim and Bayer, and thereby expanded our pipeline and increased the potential for future milestone payments.”

Founded in 2008, Gubra is a privately held pharma and biotech services company delivering scientific counselling, contract research services and discovery programs. Gubra has shown significant growth since its inception displaying a compound annual growth rate (CAGR) of 27% during the last five years whilst remaining highly profitable, and today employs more than 180 people in Hørsholm, Denmark.

Strengthening of Executive Management and Board of Directors. To prepare the company for the expected future growth, Gubra also today announces several changes to the composition of the Executive Management and the Board of Directors.

Niels Vrang, co-founder of Gubra, will take on the position as chief scientific officer (CSO) and hence become part of Executive Management.

Kristian Borbos will take on the position as chief financial officer (CFO) after the summer and will also be part of Executive Management. Kristian is today CFO in Ascelia Pharma, a listed Swedish biotech company focusing on oncology and has previously been business finance manager at Novozymes, lead investor relations manager at DONG Energy and senior analyst at Danske Bank.

Henrik Blou, CEO of Gubra, said:

“I would like to welcome our new CFO, Kristian Borbos, who will be a valuable new member of our management team at Gubra. I am also very happy with the fact, that co-founder Niels Vrang will allocate all his time to the newly created position as chief scientific officer, securing the high scientific standards that Gubra has become known for.”

Jacob Jelsing, co-founder of Gubra, has been elected chairman of the board, while Alexander Martensen-Larsen, who joined the Board as an independent member earlier this year, has been elected vice chairman. Lawyer Steffen Theodor Petersen will continue in his position as member of the board.

Alexander Martensen-Larsen, vice chairman, said:

“As the latest newcomer to the Board, I have been extremely impressed with what I have experienced. Gubra has not only a unique and highly profitable business model. The two founders, the leadership team, and the many skilled employees, have also done a great job building a strong research organization and lately adding a robust development pipeline to fuel future value creation.”




Sofia Pitt Boserup

Lead Communication Partner
+45 41889586
[email protected]


About Gubra

Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at

The post Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments appeared first on Gubra.

Share this page

For further information

Contact us


Hørsholm Kongevej 11B
2970 Hørsholm

[email protected]
+45 3152 ­2650

Back To Top